BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/12/2021 5:45:28 AM | Browse: 376 | Download: 694
 |
Received |
|
2021-02-07 19:21 |
|
Peer-Review Started |
|
2021-02-07 19:27 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-03-16 06:27 |
|
Revised |
|
2021-04-11 20:22 |
|
Second Decision |
|
2021-06-25 13:50 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-06-25 14:14 |
|
Articles in Press |
|
2021-06-25 14:14 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-07-08 04:25 |
|
Publish the Manuscript Online |
|
2021-07-12 05:45 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Review |
| Article Title |
Current cancer therapies and their influence on glucose control
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Carly Yim, Kerry Mansell, Nassrein Hussein and Terra Arnason |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Terra Arnason, FRCPC, MD, Academic Research, Doctor, Professor, Departments of Anatomy and Cell Biology and Medicine, Division of Endocrinology, University of Saskatchewan, Room 3654 Royal University Hospital 103 Hospital Drive, Saskatoon S7N 0W8, Saskatchewan, Canada. terra.arnason@usask.ca |
| Key Words |
Cancer therapy; Hyperglycemia; adverse drug effects; Immune checkpoint inhibitors; mTOR inhibitors; 5-fluorouracil analogs; Glucocorticoids; Diabetes mellitus |
| Core Tip |
Immune checkpoint inhibitors (ICI) rarely cause hyperglycemia, but glucose monitoring from their initiation is critical as rapid diabetic ketoacidosis can develop from underlying immune-mediated pancreatic beta-cell destruction. Therapy with mammalian target of rapamycin (mTOR) inhibitors, 5-fluorouracil (5-FU)-analogs and glucocorticoids have higher rates of hyperglycemia early in therapy that is not generally severe, but needs to be recognized and treated to optimize patient outcomes. The hyperglycemia occurring from the 5-FU and ICI classes is not reversible. The diabetes from ICIs arises from an absolute insulin deficiency vs the partial deficiency from the 5-FU class. Glucocorticoids and mTOR inhibitors predominantly cause insulin resistance. |
| Publish Date |
2021-07-12 05:45 |
| Citation |
Yim C, Mansell K, Hussein N, Arnason T. Current cancer therapies and their influence on glucose control. World J Diabetes 2021; 12(7): 1010-1025 |
| URL |
https://www.wjgnet.com/1948-9358/full/v12/i7/1010.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v12.i7.1010 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
